- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Elscint begins shipping CT Scope
Elscint of Rockleigh, NJ, has begun marketing its CT Scope interventional package for its CT-Twin and Helicat families of CT scanners. The package received 510(k) clearance in June and brings Elscint into the interventional CT segment. CT Scope was first
Elscint of Rockleigh, NJ, has begun marketing its CT Scope interventional package for its CT-Twin and Helicat families of CT scanners. The package received 510(k) clearance in June and brings Elscint into the interventional CT segment. CT Scope was first displayed at the 1996 Radiological Society of North America meeting (SCAN Special Report 12/96).
CT Scope improves the performance of the company's CT-Twin scanner by helping radiologists track the exact position of biopsy needles. The package enables users to view partially reconstructed images at a rate of six frames per second, with a delay of one second, according to Chuck Armstrong, vice president of Elscint's CT/MRI division. CT Scope includes an in-room monitor and gantry controls, as well as real-time display of images as they are collected.
Elscint combines CT Scope with the company's LaserGuide marking technology. Using lasers mounted on the front of the scanner gantry, LaserGuide's software calculates the needle angle required for a particular biopsy and marks the point of entry. The company believes LaserGuide distinguishes CT Scope from interventional CT packages marketed by other companies, such as Aspire CI from Toshiba America Medical Systems of Tustin, CA.
CT Scope lists at approximately $100,000, including LaserGuide, according to Armstrong. Elscint has sold about six of the packages in the U.S. since receiving FDA clearance.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
